Skip to main content

Generics

  • Impax adds TetraLogic Pharmaceuticals CEO to board
    HAYWARD, Calif. — Impax Laboratories has a new board member. The company announced Monday that it had appointed J. Kevin Buchi, CEO of TetraLogic Pharmaceuticals, to its board of directors. 
     
    “We are pleased to welcome Kevin to our Board,” Impax chairman Robert L. Burr said. “Kevin brings a great deal of pharmaceutical experience as an accomplished executive and director. He will provide valuable insights and perspective with respect to our operations, strategy and corporate governance.”

  • Sandoz to donate up to $10 million in generics to Americares
    PRINCETON, N.J.  — Sandoz on Tuesday announced that it would be donating up to $10 million in generic medicines annually to Americares, an organization that responds to those affected by poverty or disaster with health programs, medicine and medical supplies. The initial donation will include more than 25 Sandoz products for treatment of infections, cardiovascular condition, eyecare, skin conditions and musculoskeletal pain. 
     

  • APhA celebrates 20 years of immunizing pharmacists

  • FDA approves Lupin’s hydrocodone bitartrate, acetaminophen tablets
    SILVER SPRING, Md. — The Food and Drug Administration has approved a generic of Mikart’s hydrocodone bitartrate and acetaminophen tablets from Gavis Pharmaceuticals, Lupin’s U.S. subsidiary, the company announced Thursday. 
     

  • Survey: Doctors embrace biosimilars, but with caution
    BOSTON — A new survey from InCrowd is finding physicians more open to prescribing their patients biosimilars in the coming years, but they are also more cautious than they were six months ago about allowing pharmacy-level substitution. 
     

  • Savings from generics hit all-time high

    Generic medications saved the U.S. healthcare system more money in 2015 than ever before, according to the eighth-annual “2016 Generic Drug Savings & Access in the United States Report,” compiled by Quintiles IMS Institute on behalf of the Generic Pharmaceutical Association.

    (To view the full Category Review, click here.)

  • Coming soon: Aurobindo Pharma USA introduces new label design

    According to QuintilesIMS National Prescription Audit data from August, Aurobindo Pharma USA continues to eclipse market growth predictions, most recently moving into the Top 6 among all generic companies in prescriptions dispensed.

    (To view the full Category Review, click here.)

  • Allergan, Amgen submit application for possible Avastin biosimilar
    THOUSAND OAKS, Calif. — Amgen and Allergan on Wednesday announced their submission of a biologics license application to the Food and Drug Administration for ABP 215, a potential biosimilar of Avastin (bevacizumab). The companies said ABP 215 is the most advanced of the four oncologic biosimilars they are developing, and they believe it’s the first submission for an Avastin biosimilar. 
     
X
This ad will auto-close in 10 seconds